68 results about "Eosinophilic Granulocyte" patented technology

The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e g, esophagus, stomach, small intestine and colon), or lung.

The invention discloses a method for differential counting of white blood cells based on morphology. The method includes the steps that after Wright stain is conducted on peripheral blood smears, a microscope is used for collecting an image; after the image is processed by a computer system, morphology parameter analysis is conducted on the white blood cells, and the white blood cells are divided into a lymphocyte area, a monocyte area, a granulocyte area and a cell extinction area; the morphology parameter analysis is conducted on the area cells which are divided in the previous step, and the cells are further divided into monocytes, lymphocytes, eosinophilic granulocytes and neutrophile granulocytes precisely; the differential counting statistics are carried out on the variety of the divided cells. The computer system is used for analyzing the processed image, several simple morphology parameters are used for making a two-dimensional scatter diagram, all the cells are presented in a statistical diagram mode, the white blood cells can be classified rapidly and precisely, white blood cell counting is automatic, compared with manual counting, the procedures are simple and fast, the diagnose speed is greatly increased, and accuracy is improved substantially.

Disclosed is the use of an adhesion molecule inhibitor that is effective in the prevention and treatment of inflammatory diseases caused by infiltration of leukocytes such as monocytes, lymphocytes and eosindphils, by inhibiting cell infiltration which mediates adhesion molecules, especially adhesion molecule VLA-4. Since the spiro acid derivatives according to the present invention are excellent in the effect of inhibiting cell adhesion via adhesion molecules, especially adhesion molecule VLA-4, they are useful as therapeutic drugs against various inflammatory diseases. For example, provided are the spiro derivative and the adhesion molecule inhibitor which includes as an active ingredient the spiro derivative as shown by the below formula (18).

A method for classifying leukocytes in animal blood is described. In the method, a measurement sample is prepared by mixing a canine or feline blood sample with a lysing reagent. Erythrocytes are lysed and leukocytes are shrunk in the measurement sample. The data correlated with the size of leukocytes in the measurement sample are measured. The leukocytes, on the basis of the measured data, are classified into a first group containing lymphocytes, a second group containing neutrophils and monocytes and a third group containing eosinophils.

The invention discloses polypeptide, a preparation method and an application thereof. An amino acid sequence of the polypeptide is shown as SEQID NO:1. The polypeptide provided by the invention is a bioactive polypeptide extracted from skins of northern leopard frogs, is leucine-valine-arginine-glycine-cysteine-tryptophan-threonine-lysine-serine-tyrosine-proline-proline-lysine-proline-cysteine-phenylalanine-valine-arginine polypeptide, can penetrate in unilamellar lipid vesicles with negative charges, inhibit formation of eosinophilic granulocyte and granulocyte-macrophage colonies and reduce activity of eosinophilic granulocyte for forming precursor cells and mast cells, and achieves the object of treating allergic rhinitis and asthma syndrome by combining active centers of tryptase to inhibit the activity of protease.

A method is described for diagnosing eosinophilic esophagitis by studying the levels of expression of novel markers, including ALOX15 or metabolites thereof, TNFAIP6, FLG, SLURP1, or CRISP3. Also described are methods for treating eosinophilic esophagitis.

The invention discloses a reagent for classifying leukocytes, which can be used for classifying leukocytes into five groups corresponding to lymphocytes, monocytes, eosinophilic granulocytes, neutrophilic granulocytes and basophilic granulocytes. The reagent comprises a buffering agent and a hemolytic agent, wherein the hemolytic agent comprises at least two types of betaine type amphoteric surfactants. The reagent can be applied in wide pH value and temperature ranges, does not damage the leukocytes and can be used for accurately classifying white blood cells.

The present invention is directed to methods of identifying women at increased risk of having ovarian cancer. Identification is based upon the extent to which biological samples derived from the women exhibit elevated levels of eosinophil-derived neurotoxin (EDN).

The invention provides medicine for treating asthma. The medicine is glycoprotein, mixture of polysaccharide and protein, polypeptide or protein. The medicine has the advantages that the bronchial hyperresponsiveness of a mouse asthma model can be effectively lowered, the tracheospasm can be relieved, and airway pressure-time index (APTI) is 726-880 per second centimeter water column; the inflammation in the lung can be treated effectively, inflammatory cell infiltration can be reduced, and the percentage of eosinophilic granulocyte is 14.6-16.6%; the gamma-interferon (IFN-gamma) and antibody which are capable of inhibiting asthmatic attack can be increased, and the contents of interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-13 (IL-13) which can induce the asthma can be lowered; the medicine is safe, efficient, free of side effect, quick in action during asthma preventing and treatment, capable of relieving chest distress and short of breath and evident in curative effect on the asthma.

The invention discloses a cranberry extract, which is characterized in that the cranberry extract is extracted by adopting a countercurrent extraction method. The countercurrent extraction method comprises the following steps of: (1) smashing cranberry fruits; and (2) adding ethanol solution with a PH value being 1.0-3.0, and mass fraction being 65-85 percent, carrying out countercurrent extracting for 4-6 hours at the temperature of 30-60 DEG C, filtering, merging and collecting filter liquor, and concentrating to obtain the cranberry extract. Due to the adoption of the countercurrent extraction method, original anthocyanin ingredient in cranberry can be fully extracted, and compared with a method in the prior art, the countercurrent extraction method has the characteristics that the material processing is easier, the solvent is saved, the extraction efficiency is high, the cost is low, and the like, and is applicable to industrial production; and in addition, the cranberry extract has substances capable of inducing eosinophilic granulocyte to apoptosis and activating MBP kinase.

The invention discloses a method for establishing an eosinophilic granulocyte proportion model by utilizing a nasal polyp pathological picture, and the method comprises the following steps: preparingdata, manufacturing nasal polyp into a slide, scanning by using a digital pathological instrument to obtain a WSI picture, and cutting the WSI picture to obtain small pathological pictures; dividing all the small pathological pictures into training set data and test set data according to a set proportion; establishing the eosinophilic granulocyte proportion model; performing training on an ImageNet data set by adopting an Inception V3 model to obtain model parameters, removing the last full connection layer FC of the model, adding a full connection layer FC, wherein only one neuron is arranged in the full connection layer FC, and no activation function is adopted; setting a loss function to employ a mean square error MSE, and setting a learning rate lr. The method is applied to a chronicnasosinusitis nasal polyp pathological auxiliary diagnosis system, and the eosinophilic granulocyte proportion on a pathological picture is rapidly and accurately obtained through learning and training.

The invention discloses a method for establishing an airway-free high-reactivity eosinophilic granulocyte airway inflammatory mouse model. The method comprises the following steps of: 1. preparation of a mouse: preparing a SPF (Specific Pathogen Free) level female Balb / c mouse with 5-6 week-ages; 2. molding of the mouse: respectively injecting 200mul of physiological saline solution mixed suspension of 10mug of chicken ovalbumin and 1.3mg of aluminum hydroxide into the abdominal cavity of the mouse at the 0th, the 7th and the 14th days of an experiment for carrying out sensitization; carrying out light anaesthesia on the mouse at the 21st, the 22nd and the 23rd days of the experiment, and carrying out nasal dripping excitation through 50mul of chicken ovalbumin solution with the mass percent concentration of 0.02 percent; and 3. treatment of the mouse: carrying out wounded lung function detection and bronchoalveolar lavage fluid cellular classification counting analysis on the mouse after the excitation of the last time for 24-48 hours, collecting the lung of the mouse to observe the histological change of the lung to obtain the hominine airway-free high-reactivity eosinophilic granulocyte airway inflammatory mouse model.

Assay methods for analyzing whole blood to detect histamine H4 receptor-mediated effects, such as eosinophil shape change, cytoskeletal change, adhesion molecule up-regulation, or calcium flux are described. Such methods are useful in clinical and diagnostic applications.

The present invention discloses extract of Hippophae rhamnoides seed having effects of inducing apoptosis, antihypersensitivity and antiinflammation. The present extract can be obtained by a method comprising extracting Hippophae rhamnoides seed with ethanol twice, concentrating the extract combined under reduced pressure, dissolving the resulting brown residue in water, extracting sequentially with ethyl ether, ethyl acetate, butanol three times respectively, concentrating ether phase, applying the resulting brown oil to silica gel column, eluting with ethyl acetate, and collecting the elutes. The present extract has the activity of inducing apoptosis of eosinophil granulocyte; can activate MBP kinase; and serve to induce apoptosis of eosinophil granulocyte in various diseases caused by excess eosinophil granulocyte.

The invention discloses an application of urolithin A in prevention and treatment of allergic rhinitis and allergic asthma, and the urolithin A is used for treating allergic airway diseases by adjusting lung tissue TXNIP / NLRP3 pathway related proteins. The inventor finds that the urolithin A can significantly improve multiple inflammatory indexes of mice with allergic airway diseases, and compared with ellagic acid, the urolithin A has the effects of improving the nose scratching frequency of the mice in a disease model group, reducing the levels of IL-5, IL-4 and IL-18 in BALF, and improving the inflammatory index of the mice with allergic airway diseases. The traditional Chinese medicine composition has better effects on relieving lung eosinophilic granulocyte infiltration and goblet cell hyperplasia, reducing pathological scores of bronchial and perivascular inflammatory cell infiltration degrees, increasing the level of anti-oxidation factors GSH of lung tissues, reducing TXNIP, ASC and IL-1beta protein expression of the lung tissues and reducing the proportion of NLRP3 and TXNIP positive cells.

The invention relates to a method for differentiating a shellfish granular blood cell types. The method comprises the following steps of: (1) dissolving neutral red in a phosphate buffer solution at a mass ratio of 100:(1-3), filtering and then storing at a temperature of 4-5 DEG C, and diluting before use; (2) preparing a shellfish blood cell suspension, taking 1-2 ml of a neutral red working solution and 1-2 ml of the blood cell suspension and mixing evenly in a cell culture plate hole, dyeing for 30-40 minutes, then dropwise adding a drop of evenly mixed solution on a glass slide, and then observing the type of the shellfish granular blood cells through microscopic examination. Compared with the traditional MGG (May-Grunwald -Giemsa) dyeing method, the method provided by the invention is free of cell fixation, less in operation to the cells, and capable of clearly differentiating the granular blood cell type; therefore, a very convenient and practicable method is provided for studying the phagocytic capability, athletic capability, reactive oxygen generation capability and wound repair capability of eosinophilic granulocyte and basophilic granulocyte from the aspect of living cells.

The invention discloses an eosinophil analogue, a preparation method of the analogue and a whole blood quality control substance containing the eosinophil analogue, wherein, the eosinophil analogue is prepared from neutrophils. The analogue can accurately simulate the characteristic of eosinophils, thus the analogue can be applied to quality control for analytic determination of the eosinophils; and the analogue takes the neutrophils, especially the neutrophils of mammals as raw materials, thus having the advantages of available raw material sources, simple production process, low production cost, good stability and good repeatability among production batches.

The invention discloses preparation and application of a fusion protein genetically engineered bacterium of coccidium antigen peptide / IL5. The amino acid sequence of the fusion protein is shown as SEQ ID No. 1. The sequence of the coding gene of the gene is shown as SEQ ID No.2. The protein provided by the invention has remarkable prevention, treatment and regulation effects on avian coccidiosis. The cationic polypeptide compound expressed by the food-grade bacillus subtilis causes acquired immune response of animal intestinal tracts through mucosal immunity, and an anti-coccidiosis antibody is generated. The interleukin 5 is an eosinophilic granulocyte activating factor and can activate eosinophilic granulocytes in intestinal tracts, secrete anti-parasitic active substances and repair intestinal mucosa damage caused by coccidium infection.

The invention provides an application of amniotic fluid stem cells in preparation of drugs for treating lupus nephritis. The amniotic fluid stem cells can down-regulate the expression of pro-inflammatory factors IL-17 and IL-12p40 and up-regulate the expression of an anti-inflammatory factor IL-1ra, and meanwhile, can down-regulate pro-inflammatory M1 macrophages, dendritic cells and eosinophils and up-regulate anti-inflammatory Th2 cells so as to exert the treatment effect. The amniotic fluid cells have the characteristics of being easy to obtain, free of ethical disputes, simple to culture,strong in differentiation capability and low in immunogenicity. A new strategy is provided for treatment of systemic lupus erythematosus and lupus nephritis which is a complication of systemic lupus erythematosus.

The present invention discloses an artemisia ordosica root extract and a preparation method and an application thereof. The preparation method of the artemisia ordosica root extract comprises the following steps: drying and crushing artemisia ordosica roots and adding an ethanol solution for ultrasonic extraction; then mixing each extract and conducting concentrating and drying to obtain an extract A; and (2) dissolving the extract A with distilled water, and sequentially conducting extraction with petroleum ether, ethyl acetate and n-butanol; and collecting an ethyl acetate layer extract, andconducting concentration under reduced pressure and drying to obtain a finished product. The artemisia ordosica root extract contains 50-90% of total flavonoids, and eriodictyol, isosakuranetin, naringenin, hydroxygenkwanin, genkwanin, acacetin, diosmetin, glycitein, isorhamnetin, morin and quercetin with the total content of more than 2%. The artemisia ordosica root extract can obviously reduceallergic rhinitis symptoms of guinea pigs, also reduces levels of inflammatory factors of histamine, ovalbumin specific IgE, IL-2 / 4 / 10, IFN-gamma, ICam-1, etc. in serum of the guinea pigs, and can also reduce infiltration of eosinophilic granulocyte of nasal mucosa of nasal cavities of the guinea pigs.

The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and agonists, antibodies or antagonists specifically binding EBPH, in the prevention and treatment of diseases associated with expression of EBPH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding EBPH for the treatment of diseases associated with the expression of EBPH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding EBPH.

The invention discloses application of a perilla leaf extract to preparation of a medicament for treating the chronic obstructive pulmonary disease (COPD). The perilla leaf extract disclosed by the invention has a reversing effect on the cigarette-induced COPD model mouse lung inflammation pathological injury; generation of inflammatory cytokines of TNF-alpha and IL-1beta in the Bronchoalveolar Lavage Fluid (BALF) of a model mouse can be obviously inhibited; and the total number of leukocytes and the recruitment of lymphocytes and eosinophilic granulocyte in the BALF of the model mouse are obviously inhibited.

The invention belongs to the technical field of medicines for treating asthma, and particularly relates to application of polygonatum odoratum polysaccharide in preparation of medicines for treating asthma. Experimental research finds that the polygonatum odoratum polysaccharide can improve release of allergic asthma related cell factors in an airway, reduce the number of eosinophilic granulocytes, reduce serum total IgE, improve allergy conditions and improve pathological conditions such as lung inflammatory infiltration, goblet cell metaplasia and pulmonary parenchyma of asthma mice. Therefore, the polygonatum odoratum polysaccharide can be used for preparing the medicine for treating asthma.

The present invention provides a method of determining the susceptibility of a subject to treatment with a leukotriene modifier by determining the subject's cysteinyl leukotriene (CysLT) level and the subject's level of eosinophilic airway inflammation and identifying a subject with a high ratio of CysLT levels to eosinophilic airway inflammation as susceptible to treatment with the leukotriene modifier. Also discussed is a method of treatment of subjects who are susceptible to treatment that includes administering a leukotriene modifier to such a subject.

The invention relates to pharmaceutical compositions comprising 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide for use in the treatment of acute exacerbations of chronic obstructive pulmonary disease in human patients having <2% blood eosinophils. The invention also relates to pharmaceutical compositions for the treatment of AECOPD in a human patient having <2% blood eosinophils, comprising administering to the patient three separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide over a period of not longer than ten days with at least one day between every dose.

The invention discloses a traditional Chinese medicine formula for treating chronic urticaria. The traditional Chinese medicine is characterized by being prepared from, by weight, 10-15 g of astragalus membranaceus, 10-15 g of fleece flower roots, 10-15 g of rhizoma atractylodis macrocephalae, 10-12 g of angelica sinensis, 10-12 g of cortex dictamni, 10-12 g of common peony roots, 10-12 g of saposhnicovia divaricata, 6-10 g of periostracum cicada, 6-10 g of scorpion and 6-10 g of centipede. By the adoption of the traditional Chinese medicine formula, wheals can be eliminated and pruritus can be stopped after one treatment course for less serious cases, and blotches and pruritus are eliminated after two to three treatment courses for serious cases. The skin scratch test is negative, and blood routine reexamination shows that the number of eosinophilic granulocytes is reduced to be normal.

The present invention relates to a composition for treating atopic dermatitis comprising hirsutanonol as an active ingredient. Hirsutanonol or oregonin as the active ingredient of the present composition decreases the number of eosinophil increased in atopic dermatitis and regulates expression amounts of immune regulatory cytokines, IL-4, IL-5, IL-10 and IL-13 associated with atopic dermatitis. In addition, hirsutanonol and oregonin increase MBD (mouse beta-defensin)-1, MBD-2 and MBD-3 expression and decrease COX-2 and iNOS expression in mouse animal model of atopic dermatitis. Hirsutanonol and oregonin as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis.

The invention discloses application of a perilla leaf extract to preparation of a medicament for treating and / or preventing asthma. The perilla leaf extract disclosed by the invention has a reversingeffect on the lung inflammation pathological injury of an asthma model mouse; generation of inflammatory cytokines of TNF-alpha, IL-1beta and the like in Bronchoalveolar Lavage Fluid (BALF) of the model mouse can be obviously inhibited; and the total number of leukocytes and the recruitment of lymphocytes and eosinophilic granulocyte in the BALF of the model mouse are obviously inhibited. The asthma effect of the model mouse is obviously improved.

The invention provides a primer group and a kit for detecting mRNA (messenger Ribonucleic Acid) expression of cationic protein of human eosinophilic granulocyte, and relates to the technical field of biological detection. The primer group disclosed by the invention comprises an ECP-F, an ECP-R, a GAPDH-F and a GAPDH-R; the nucleotide sequence of the ECP-F is as shown in SEQ ID NO. 1; the nucleotide sequence of the ECP-R is as shown in SEQ ID NO. 2; the nucleotide sequence of the GAPDH-F is as shown in SEQ ID NO. 3; and the nucleotide sequence of the GAPDH-R is as shown in SEQ ID NO. 4. The invention further provides a kit comprising the above primer group, the expression level of human ECP mRNA can be quantitatively detected by a one-step method, and a detection means with high accuracy, wide detection range and high sensitivity is provided for detection of the protein.

A therapeutic or prophylactic agent for radiation damage associated with radiation exposure, comprising an eosinophil-removing agent as an active ingredient and the like are provided as a technique for efficiently treating or preventing radiation damage associated with radiation exposure. According to the therapeutic or prophylactic agent comprising an eosinophil-removing agent according to the present invention, by suppressing migration and / or infiltration into target tissue and / or proliferation in the tissue of eosinophils and / or inhibiting the activity or function of the eosinophils, pathological conditions such as inflammatory responses and fibrosis of tissue can be suppressed to effectively treat or prevent radiation damage. Moreover, effective radiation therapy can be performed by suppressing radiation damage.